Study identifies sildenafil as candidate drug for Alzheimer’s disease

Cleveland Clinic research identifies sildenafil as candidate drug for Alzheimer's disease
According to findings published in Nature Aging, the research team, led by Feixiong Cheng, Ph.D., of Cleveland Clinic’s Genomic Medicine Institute, determined that sildenafil is associated with 69% reduced incidence of Alzheimer’s disease. Credit: Cleveland Clinic

A new Cleveland Clinic-led study has identified sildenafil—an FDA-approved therapy for erectile dysfunction (Viagra) and pulmonary hypertension (Ravatio)—as a promising drug candidate to help prevent and treat Alzheimer’s disease.

According to findings published in Nature Aging, the research team, led by Feixiong Cheng, Ph.D., of Cleveland Clinic’s Genomic Medicine Institute, used computational…

Read more…